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Examining Zika Virus: Transmission, Diagnosis, Treatment, and Prevention 
Noura Taybeh 
Abstract: The Zika virus is a mosquito-borne virus that was first isolated in Uganda in 1947 and has since caused outbreaks in many parts of the world. It 
has multiple routes of transmission and may cause acute illness and death if not treated. The Zika virus becomes a major concern if transmitted from mother 
to fetus as it increases the chance of birth defects and developmental problems to the unborn baby. This article highlights the importance of early diagnosis 
and describes Zika virus’ transmission, treatment, and prevention. 
ika virus is a viral infection that is carried by infected Aedes
aegypti mosquitoes and transmitted through bites. The virus
was discovered in 1947 in Uganda in monkeys and then was 
identified in humans in 1954.1 Aedes aegypti is also known to 
transmit yellow fever, West Nile virus, and Japanese encephalitis.2 
The Zika virus is still circulating in many parts of the world with 
documented outbreaks affecting regions such as Mexico, Central 
America, South America, and the Caribbean. The virus’ incubation 
period is estimated between 2-14 days. While most people do not 
develop symptoms, they can last between 2-7 days and consist of 
fever, muscle and joint pain, headache, swollen lymph glands, 
malaise, and rash.  Less common symptoms are edema, vomiting, 
and abdominal pain.3  Currently, there is no vaccination to prevent 
or anti-viral medication to treat the Zika virus. The best protection 
against Zika is preventing mosquito bites and avoiding areas with 
the virus. The disease continues to be a public health concern, 
especially for unborn children with infected mothers. Transmission, 
diagnosis, and treatment of the Zika virus is still a main concern, as 
it can cause extensive illnesses and even death. 
The Zika virus has multiple modes of transmission including 
mosquito bites, sexual transmission, blood transfusion, and 
mother-to-child transmission. Sexual transmission, otherwise 
known as non-vectorial transmission, occurs when an infected 
person passes the virus through intercourse with his or her 
partner.4 Although the reported cases of transmission through 
blood transfusion are low, a study in Brazil showed that some 
blood donors were infected and asymptomatic at the time of 
donation. However, post-donation surveillance showed that the 
infected donors started to experience symptoms shortly after 
blood donation. This method of transmission occurred during the 
French Polynesian outbreak in 2013, when 2.8% of blood donors 
tested positive for Zika virus. The Zika virus has been detected in 
breast milk, but it is unclear whether the virus is transmissible to 
children via breastfeeding.5  A study published by the Infectious 
Diseases Society of America in 2018 found that mother-to-child 
transmission of the virus can occur during breastfeeding, during 
delivery and close contact between mother and child.6 If the virus 
is passed to the fetus during pregnancy, the developing fetus has 
an increased chance of birth defects and developmental problems. 
Developmental problems may include hearing loss, decreased 
brain tissue with brain damage, eye defects, seizures, problems 
with joint and limb movement, and microcephaly; a condition 
where the head is significantly smaller than normal.7  One severe 
complication is Guillain-Barre syndrome (GBS). GBS is a rare 
neurological disorder where the immune system attacks the 
peripheral nervous system. GBS symptoms present with weakness  
in muscles including fatigue, dysphagia, and may result in 
paralysis. 8
Zika virus can be diagnosed using two different tests, one 
detecting antibodies and the other identifies the genetic 
footprint of the virus. The genetic test, known as RNA nucleic acid 
amplification test (NAAT). This test identifies the infection by 
confirming the presence of the virus’ genetic material RNA. In 
contrast, the tracing of the virus antibodies known as 
immunoglobulin antibody test (IgM). The IgM antibodies are 
detectable 1-12 weeks post exposure. The NAAT test is more 
specific in detecting the virus but is less sensitive and could give 
false-negative results, while the IgM antibodies test is more 
sensitive but less specific, meaning it could detect similar viruses 
instead of just the Zika virus. The two tests can be performed 
concurrently for increased reliability in diagnosing infection.9 
Prevention and treatment of symptoms are key. Avoid mosquito 
bites by using mosquito repellents and wear protective clothing. 
Zika may be prevented by avoiding travel to Zika-endemic areas. 
In particular, pregnant women in any trimester or women trying 
to become pregnant should avoid these areas.  The typical 
recommendations for virally infected patients are to drink plenty 
of fluids to prevent dehydration, rest to help the body combat 
the infection, and pain relief medication to help with fever and 
pain. Currently, there is no specific antiviral treatment for the Zika 
disease. The National Institute of Health (NIH) began testing a 
Zika virus vaccine in 2016. The DNA-based Zika vaccine that 
entered phase two of clinical trials could prevent microcephaly 
and other congenital defects caused by the Zika virus.10 
The Zika virus remains a public health concern. The Zika virus is 
transmitted through various means such as mosquito bites, 
sexual transmission, mother-to-child, and blood transfusion. At 
this time, taking precautions is the primary way to protect against 
the Zika virus transmission. The future may show promise for 
development of vaccinations or potential treatment for the Zika 
virus.   
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